GlaxoSmithKline posted an 11 percent rise in second quarter profit due to its sales in emerging markets. The company, the second largest by revenue, has contracts for 195 million doses of swine flu vaccine and expects to make $2.1 billion in sales next year but still the company struggles to maintain margins after loss of patents. The outbreak has claimed 31 lives in Britain but CEO Andrew Witty maintains that the company is not trying to generate huge amounts of profit although it charges £6 for a shot of Relenza (its swine flu vaccine), which is said to cost as little as a pound to manufacture. Developing nations pay much less for the vaccine.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지